Clinical trials: Relapsed Hematologic Malignancy, active
Multiple Myeloma, Immune System Diseases
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Trial name
- NCT03672318
- Testing
- CAR138 T Cells
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Relapsed Acute Myeloid Leukemia
Imetelstat Combinations in Relapsed AML
IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML.
- Trial name
- IMAGINE (NCT07320235)
- Testing
- Imetelstat, Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Douglas Tremblay
B-ALL
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT04499573
- Testing
- CD19/CD22 CAR-T
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Multiple Myeloma
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
- Trial name
- MM (NCT04960579)
- Testing
- P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
- Where
- 23 sites in United States
- Volunteers
- 275 people
- Sponsor
- Poseida Therapeutics, Inc.
Hairy Cell Leukemia
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Background: Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies.
- Trial name
- NCT01059786
- Testing
- Pentostatin, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Primary Plasma Cell Leukemia
Study of CT071 Injection in RRMM or PPCL
A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia
- Trial name
- NCT05838131
- Testing
- Experimental: CAR-T cells Infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL)
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
- Trial name
- COURAGE (NCT06914037)
- Testing
- CHT101
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Richter Syndrome
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
The STELLAR trial will assess the effect of acalabrutinib taken in combination with CHOP-R compared to taking CHOP-R alone in patients with newly diagnosed Richter's Syndrome (RS).
- Trial name
- STELLAR (NCT03899337)
- Testing
- Acalabrutinib, Cyclophosphamide, Doxorubicin
- Where
- 17 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Birmingham
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Multiple Myeloma, Relapse Multiple Myeloma
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
This is an open label, abbreviated (3+3) dose escalation study in subjects with RRMM, followed by an extension phase at the selected safe dose.
- Trial name
- NCT05243212
- Testing
- CAR-BCMA
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Sheba Medical Center
CD19 Positive, CD20 Positive
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's…
- Conditions
- CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04007029
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies.
- Conditions
- Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT03932331
- Testing
- Acalabrutinib
- Where
- 23 sites in China
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Hematologic Malignancy, AML
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN
- Trial name
- NCT05476770
- Testing
- Tagraxofusp, Fludarabine, Cytarabine
- Where
- 31 sites in United States, Australia
- Volunteers
- 54 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Multiple Myeloma in Relapse
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies.
- Trial name
- AmbuSpé (NCT06846905)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Toulouse
Myelofibrosis
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to…
- Trial name
- NCT04576156
- Testing
- Imetelstat, Best Available Therapy (BAT)
- Where
- 144 sites in United States, Argentina and 24 more
- Volunteers
- 327 people
- Sponsor
- Geron Corporation
Relapsed/Refractory AML, AML, Adult
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory…
- Conditions
- Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
- Trial name
- NCT04623944
- Testing
- NKX101 - CAR NK cell therapy
- Where
- 8 sites in United States
- Volunteers
- 61 people
- Sponsor
- Nkarta, Inc.
Acute Myeloid Leukemia
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia…
- Trial name
- RIVER-81 (NCT06191263)
- Testing
- RVU120, Venetoclax
- Where
- 37 sites in France, Italy and 2 more
- Volunteers
- 98 people
- Sponsor
- Ryvu Therapeutics SA
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with…
- Trial name
- NCT04203316
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 28 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Acute Myeloid Leukemia
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.
- Trial name
- NCT06445907
- Testing
- Azacitidine, Venetoclax, Q702
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.